Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2020 05:00 ET | Source: Editas Medicine, Inc.; Allergan plc

Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

AGN-151587 (EDIT-101) is the first in vivo CRISPR medicine to be administered to patients Additional patient enrollment to the BRILLIANCE Clinical Trial is ongoing DUBLIN, Ireland and CAMBRIDGE,...
February 26, 2020 16:02 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update

Announcement of first patient dosing with EDIT-101 (AGN-151587) expected in 1Q20 Plan to file IND for EDIT-301 for sickle cell disease by end of 2020 Research collaboration with Sandhill...
February 19, 2020 16:02 ET | Source: Editas Medicine, Inc.

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update

CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
January 13, 2020 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference

Provides updates on advancements in in vivo and engineered cell medicine programs Details timeline to filing an IND for EDIT-301 for the treatment of sickle cell disease CAMBRIDGE, Mass., Jan. 13,...
January 13, 2020 08:55 ET | Source: Editas Medicine, Inc.

Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer

CAMBRIDGE, Mass. and DALLAS, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular immuno-oncology...
January 10, 2020 16:30 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports Inducement Grants to New Chief Financial Officer

CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly...
January 09, 2020 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth

Michelle Robertson joins as Chief Financial Officer Manufacturing veteran Harry Gill joins in newly created role of Senior Vice President, Operations CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE...
January 02, 2020 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
December 09, 2019 18:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced in vivo proof-of-concept data supporting the development...
November 12, 2019 07:02 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Third Quarter 2019 Results and Update

Amended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine Appointed Judith R. Abrams, M.D., as Chief Medical Officer EDIT-101...